CureVac's coronavirus vaccine candidate triggered immune response in animal tests

Germany's unlisted CureVac said its experimental coronavirus vaccine was shown to trigger an immune response in animals when given a low dose and the biotech firm was looking at carrying out its first human trials in June. It said on Thursday that the data supported its expectations that "the vaccine candidate has the potential to induce a strong immunologic response to neutralise SARS-CoV-2." The company, in which SAP co-founder Dietmar Hopp owns a stake of more than 80%, plans to initiate the first clinical trial in healthy volunteers in June, it said.

from Yahoo News - Latest News & Headlines https://ift.tt/3dIoWq4